MicroVention and Terumo Corporation Announce Data from Multicenter GREAT Study

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

May 7, 2-17

MicroVention, Inc., a wholly-owned subsidiary of Terumo Corporation, announced today that the multicenter GREAT study achieved its primary and secondary endpoints. The primary endpoint of the study was met with statistical significance showing lower adverse composite outcomes in the patients treated with 2nd generation HydroCoil® Embolic System coils when compared to bare platinum coils.

MicroVention notes the GREAT study (German Randomized Endovascular Aneurysm Trial) was a prospective, randomized, controlled trial that enrolled 513 patients at 22 hospitals in France and Germany. The adverse event primary endpoint was a composite of major aneurysm recurrence at 18 months, retreatment at 18 months, morbidity preventing angiographic follow-up, and all deaths regardless of cause. Investigators treated medium-sized (4-12mm) ruptured and unruptured intracranial aneurysms using at least 50% hydrogel coils by length or all bare platinum coils. Principal Investigator for the trial, Professor Christian Taschner from the University of Freiburg, Germany presented the study data at the 2017 International Stroke Conference in Houston, Texas, USA on February 23rd, 2017.

The GREAT trial results showed significant benefits of hydrogel technology, noted Professor Taschner.

“Aneurysm treatment technology is evolving quickly. It is important to understand the safety and efficacy of new devices through sound scientific methods. I was intrigued by the opportunity to test whether MicroVention’s unique hydrogel technology can improve patient outcomes in a wide-range of aneurysms,” commented Professor Taschner. “We are pleased that this independent study showed that hydrogel technology reduces a composite of adverse events, retreatments, morbidity and mortality compared to traditional bare platinum coils.”

“The results of the GREAT randomized trial demonstrate the efficacy of aneurysm treatment using our hydrogel coils and are aligned with the results of other clinical studies on this technology,” added Richard E. Cappetta, President and CEO of MicroVention, Inc.

MicroVention’s 2nd generation HydroCoil Embolic System features a non-bioactive, inert hydrogel core that absorbs water from the blood and surrounding tissue, to create a stable, mechanical platform for natural tissue proliferation and long-term aneurysm occlusion. HydroFrame®, HydroFill® and HydroSoft® Embolic Coils can be used exclusively or in conjunction with traditional bare platinum coils to safely and effectively embolize a wide range of aneurysms and neurovascular lesions.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.